Top

Current Oncology Reports

Published in:

Open Access 19-03-2024 | Acute Myeloid Leukemia | REVIEW

Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

Authors: Michael Wysota, Marina Konopleva, Shane Mitchell

Published in: Current Oncology Reports | Issue 4/2024

Abstract

Purpose of Review

This review seeks to identify and describe novel genetic and protein targets and their associated therapeutics currently being used or studied in the treatment of acute myeloid leukemia (AML).

Recent Findings

Over the course of the last 5–6 years, several targeted therapies have been approved by the FDA, for the treatment of both newly diagnosed as well as relapsed/refractory AML. These novel therapeutics, as well as several others currently under investigation, have demonstrated activity in AML and have improved outcomes for many patients.

Summary

Patient outcomes in AML have slowly improved over time, though for many patients, particularly elderly patients or those with relapsed/refractory disease, mortality remains very high. With the identification of several molecular/genetic drivers and protein targets and development of therapeutics which leverage those mechanisms to target leukemic cells, outcomes for patients with AML have improved and continue to improve significantly.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Cancer stat facts: leukemia, acute myeloid leukemia (AML). National Cancer Institute, DCCPS, Surveillance Research Program. 2023. https://seer.cancer.gov/statfacts/html/amyl.html

Rausch C, Rothenberg-Thurley M, Dufour A, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2023;37(6):1234–44. https://doi.org/10.1038/s41375-023-01884-2.CrossRefPubMedPubMedCentral

Sasaki K, Ravandi F, Kadia TM, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127(12):2049–61. https://doi.org/10.1002/cncr.33458.CrossRefPubMed

Kantarjian H, Kadia T, DiNardo C, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11(2):41. https://doi.org/10.1038/s41408-021-00425-3.CrossRefPubMedPubMedCentral

DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020;136(9):1023–32. https://doi.org/10.1182/blood.2019001982.CrossRefPubMedPubMedCentral

Ganzel C, Sun Z, Cripe LD, et al. Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience. Am J Hematol. 2018;93(8):1074–81. https://doi.org/10.1002/ajh.25162.CrossRefPubMedPubMedCentral

Bhola PD, Letai A. Mitochondria-judges and executioners of cell death sentences. Mol Cell. 2016;61(5):695–704. https://doi.org/10.1016/j.molcel.2016.02.019.CrossRefPubMedPubMedCentral

Letai A, Sorcinelli MD, Beard C, et al. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 2004;6(3):241–9. https://doi.org/10.1016/j.ccr.2004.07.011.CrossRefPubMed

Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17. https://doi.org/10.1158/2159-8290.cd-16-0313.CrossRefPubMedPubMedCentral

10.

DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617–29. https://doi.org/10.1056/NEJMoa2012971.CrossRefPubMed

11.

Wei AH, Montesinos P, Ivanov V, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135(24):2137–45. https://doi.org/10.1182/blood.2020004856.CrossRefPubMedPubMedCentral

12.

•• Lachowiez CA, Atluri H, DiNardo CD. Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia. Ther Adv Hematol. 2022;13(20406207221093964. https://doi.org/10.1177/20406207221093964. This article identifies the increasing importance of incorporating Venetoclax to intensive induction chemotherapy to improve outcomes for patients with AML.

13.

Lachowiez CA, Reville PK, Kantarjian H, et al. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol. 2022;9(5):e350–60. https://doi.org/10.1016/s2352-3026(22)00076-x.CrossRefPubMedPubMedCentral

14.

Grafone T, Palmisano M, Nicci C, et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6(1): e8. https://doi.org/10.4081/oncol.2012.e8.CrossRefPubMedPubMedCentral

15.

Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089–102. https://doi.org/10.1182/blood-2010-04-261867.CrossRefPubMed

16.

Fröhling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100(13):4372–80. https://doi.org/10.1182/blood-2002-05-1440.CrossRefPubMed

17.

Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–9. https://doi.org/10.1182/blood.v98.6.1752.CrossRefPubMed

18.

Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100(1):59–66. https://doi.org/10.1182/blood.v100.1.59.CrossRefPubMed

19.

Li S, Li N, Chen Y, et al. FLT3-TKD in the prognosis of patients with acute myeloid leukemia: a meta-analysis. Front Oncol. 2023;13:1086846. https://doi.org/10.3389/fonc.2023.1086846.

20.

Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with type I versus type II FLT3 inhibitors. Blood Cancer Discov. 2021;2(2):125–34. https://doi.org/10.1158/2643-3230.bcd-20-0143.CrossRefPubMed

21.

Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–64. https://doi.org/10.1056/NEJMoa1614359.CrossRefPubMedPubMedCentral

22.

Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–40. https://doi.org/10.1056/NEJMoa1902688.CrossRefPubMed

23.

Numan Y, Abdel Rahman Z, Grenet J, et al. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022;97(3):322–8. https://doi.org/10.1002/ajh.26447.CrossRefPubMed

24.

Pratz KW, Cherry M, Altman JK, et al. Gilteritinib in combination with induction and consolidation chemotherapy and as maintenance therapy: a phase IB study in patients with newly diagnosed AML. J Clin Oncol. 2023;Jco2202721. https://doi.org/10.1200/jco.22.02721.

25.

Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845–57. https://doi.org/10.1182/blood.2021014586.CrossRefPubMedPubMedCentral

26.

•• Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571–83. This article identifies the importance of incorporating the FLT-3 inhibitor quizartinib with intensive induction chemotherapy to improve outcomes for patients with FLT-3 mutated AML.CrossRefPubMed

27.

Cortes JE, Khaled S, Martinelli G, et al. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):984–97. https://doi.org/10.1016/s1470-2045(19)30150-0.CrossRefPubMed

28.

Röllig C, Serve H, Noppeney R, et al. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021;35(9):2517–25. https://doi.org/10.1038/s41375-021-01148-x.CrossRefPubMedPubMedCentral

29.

Wei AH, Kennedy GA, Morris KL, et al. Results of a phase 2, randomized, double-blind study of sorafenib versus placebo in combination with intensive chemotherapy in previously untreated patients with FLT3-ITD acute myeloid leukemia (ALLG AMLM16). Blood. 2020;136(Supplement 1):36–8. https://doi.org/10.1182/blood-2020-137334.CrossRef

30.

Sasaki K, Kantarjian HM, Kadia T, et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019;125(21):3755–66. https://doi.org/10.1002/cncr.32387.CrossRefPubMed

31.

Yilmaz M, Muftuoglu M, Kantarjian HM, et al. Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): a phase I/II clinical trial. Journal of Clinical Oncology 2022;40(16_suppl):7036–7036. https://doi.org/10.1200/JCO.2022.40.16_suppl.7036.

32.

• Short N, DiNardo CD, Daver N, et al. Updated results from a phase I/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia. Blood. 2022;140(1):2007–9. This trial demonstrates the feasability of FLT-3 inhibition with Gilteritinib along with low intensity Azacitidine venetoclax for patients with FLT-3 mutated AML, who are unfit for intensive induction.CrossRef

33.

Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation. Biol Blood Marrow Transplant. 2016;22(6):982–90. https://doi.org/10.1016/j.bbmt.2016.01.013.CrossRefPubMed

34.

Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3–internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38(26):2993–3002. https://doi.org/10.1200/jco.19.03345.CrossRefPubMed

35.

Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021;56(5):1180–9. https://doi.org/10.1038/s41409-020-01153-1.CrossRefPubMed

36.

•• Levis MJ, Hamadani M, Logan B, et al. BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. Frankfurt, Germany: EHA 2023 Hybrid Congress; 2023. This article demonstrates the importance of maintenance FLT-3 inhibition with Gilteritinib for patients with FLT-3 mutated AML who are MRD + after induction or transplant.

37.

Im AP, Sehgal AR, Carroll MP, et al. DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014;28(9):1774–83. https://doi.org/10.1038/leu.2014.124.CrossRefPubMedPubMedCentral

38.

Ward PS, Lu C, Cross JR, et al. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem. 2013;288(6):3804–15. https://doi.org/10.1074/jbc.M112.435495.CrossRefPubMed

39.

Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–34. https://doi.org/10.1016/j.ccr.2010.01.020.CrossRefPubMedPubMedCentral

40.

Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553–67. https://doi.org/10.1016/j.ccr.2010.11.015.CrossRefPubMedPubMedCentral

41.

Chan SM, Thomas D, Corces-Zimmerman MR, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21(2):178–84. https://doi.org/10.1038/nm.3788.CrossRefPubMedPubMedCentral

42.

Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2010;28(23):3717–23.CrossRefPubMed

43.

Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28(22):3636–43.CrossRefPubMed

44.

Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Adv. 2023;7(19):5941–53. https://doi.org/10.1182/bloodadvances.2022008282.CrossRefPubMedPubMedCentral

45.

Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–31. https://doi.org/10.1182/blood-2017-04-779405.CrossRefPubMedPubMedCentral

46.

DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22(11):1597–608. https://doi.org/10.1016/s1470-2045(21)00494-0.CrossRefPubMed

47.

Venugopal S, Takahashi K, Daver N, et al. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022;12(1):10. https://doi.org/10.1038/s41408-021-00604-2.CrossRefPubMedPubMedCentral

48.

DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–98. https://doi.org/10.1056/NEJMoa1716984.CrossRefPubMed

49.

Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519–31. https://doi.org/10.1056/NEJMoa2117344.CrossRefPubMed

50.

Lachowiez CA, Loghavi S, Zeng Z, et al. A phase Ib/II study of ivosidenib with Venetoclax ± Azacitidine in IDH1-mutated myeloid malignancies. Blood Cancer Discov. 2023;4(4):276–93. https://doi.org/10.1158/2643-3230.bcd-22-0205.CrossRefPubMedPubMedCentral

51.

de Botton S, Fenaux P, Yee K, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023;7(13):3117–27. https://doi.org/10.1182/bloodadvances.2022009411.CrossRefPubMedPubMedCentral

52.

Watts JM, Baer MR, Yang J, et al. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023;10(1):e46–58. https://doi.org/10.1016/s2352-3026(22)00292-7.CrossRefPubMed

53.

Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021;137(13):1792–803. https://doi.org/10.1182/blood.2020007233.CrossRefPubMedPubMedCentral

54.

Issa GC, DiNardo CD. Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm. Blood Cancer J. 2021;11(6):107. https://doi.org/10.1038/s41408-021-00497-1.CrossRefPubMedPubMedCentral

55.

La P, Desmond A, Hou Z, et al. Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene. 2006;25(25):3537–46. https://doi.org/10.1038/sj.onc.1209400.CrossRefPubMed

56.

Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823–33. https://doi.org/10.1038/nrc2253.CrossRefPubMed

57.

Meyer C, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome including 8 novel partner genes ACTN4, C2CD3, DCP1A, FLNA, LAMC3, LOC100128568, NRIP3, and TNRC18. Blood. 2008;112(11):2047–2047. https://doi.org/10.1182/blood.V112.11.2047.2047.CrossRef

58.

Sun Y, Zhou B, Mao F, et al. HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell. 2018;34(4):643-658.e5. https://doi.org/10.1016/j.ccell.2018.08.018.CrossRefPubMedPubMedCentral

59.

Issa GC, Zarka J, Sasaki K, et al. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021;11(9):162. https://doi.org/10.1038/s41408-021-00557-6.CrossRefPubMedPubMedCentral

60.

Zarka J, Short NJ, Kanagal-Shamanna R, et al. Nucleophosmin 1 mutations in acute myeloid leukemia. Genes (Basel). 2020;11(6). https://doi.org/10.3390/genes11060649.

61.

Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21. https://doi.org/10.1056/NEJMoa1516192.CrossRefPubMedPubMedCentral

62.

Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–66. https://doi.org/10.1056/NEJMoa041974.CrossRefPubMed

63.

Brunetti L, Gundry MC, Sorcini D, et al. Mutant NPM1 maintains the leukemic state through HOX expression. Cancer Cell. 2018;34(3):499-512.e9. https://doi.org/10.1016/j.ccell.2018.08.005.CrossRefPubMedPubMedCentral

64.

Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367(6477):586–90. https://doi.org/10.1126/science.aax5863.CrossRefPubMedPubMedCentral

65.

Iwamoto M, Asakawa H, Ohtsuki C, et al. Monoclonal antibodies recognize gly-leu-phe-gly repeat of nucleoporin nup98 of tetrahymena, yeasts, and humans. Monoclon Antib Immunodiagn Immunother. 2013;32(2):81–90. https://doi.org/10.1089/mab.2012.0118.CrossRefPubMedPubMedCentral

66.

Bertrums EJM, Smith JL, Harmon L, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108(8):2044–58. https://doi.org/10.3324/haematol.2022.281653.CrossRefPubMedPubMedCentral

67.

McNeer NA, Philip J, Geiger H, et al. Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia. 2019;33(8):1934–43. https://doi.org/10.1038/s41375-019-0402-3.CrossRefPubMedPubMedCentral

68.

Shiba N, Ichikawa H, Taki T, et al. NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosomes Cancer. 2013;52(7):683–93. https://doi.org/10.1002/gcc.22064.CrossRefPubMed

69.

Mohanty S. NUP98 rearrangements in AML: molecular mechanisms and clinical implications. Onco. 2023;3(3):147–64.CrossRef

70.

Heikamp EB, Henrich JA, Perner F, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022;139(6):894–906. https://doi.org/10.1182/blood.2021012806.CrossRefPubMedPubMedCentral

71.

• Issa GC, Aldoss I, DiPersio J, et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature. 2023;615(7954):920–9245. https://doi.org/10.1038/s41586-023-05812-3. This study demonstrates the effectiveness of Menin inhibition in the relapsed refractory setting for patients with KMT2A-rearranged and NPM1 mutated AML.CrossRefPubMedPubMedCentral

72.

• Fathi A, Wang E, Issa G, et al. Activity, tolerability, and resistance profile of the menin inhibitor ziftomenib in adults with relapsed/refractory NPM1-mutated AML. Frankfurt, Germany: EHA 2023 Hybrid Congress; 2023. This study again demonstrates the effectiveness of another Menin inhibitor in relapsed refractory NPM1 mutated and KMT2a-rearranged AML.

73.

Jabbour E, Searle E, Abdul-Hay M, et al. A first-in-human phase 1 study of the menin-KMT2A (MLL1) inhibitor JNJ-75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations. Blood. 2023;142(Supplement 1):57–57. https://doi.org/10.1182/blood-2023-172422.CrossRef

74.

Issa GC, Cuglievan B, DiNardo CD, et al. Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE). Blood. 2023;142(Supplement 1):58–58. https://doi.org/10.1182/blood-2023-182337.CrossRef

75.

Perner F, Stein EM, Wenge DV, et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature. 2023;615(7954):913–9. https://doi.org/10.1038/s41586-023-05755-9.CrossRefPubMedPubMedCentral

76.

Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2(1):4. https://doi.org/10.1186/2050-7771-2-4.CrossRefPubMedPubMedCentral

77.

Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84. https://doi.org/10.1038/sj.leu.2401903.CrossRefPubMed

78.

Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100(8):2980–8. https://doi.org/10.1182/blood-2002-03-0852.CrossRefPubMed

79.

Kubasch AS, Schulze F, Giagounidis A, et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020;34(4):1182–6. https://doi.org/10.1038/s41375-019-0645-z.CrossRefPubMed

80.

Daver NG, Montesinos P, DeAngelo DJ, et al. Clinical profile of IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC), in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood 2019;134(Supplement_1):734–734. https://doi.org/10.1182/blood-2019-128648.

81.

Daver N, Montesinos P, Aribi A, et al. Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML). Blood. 2022;140(Supplement 1):145–9. https://doi.org/10.1182/blood-2022-158030.CrossRef

82.

Daver N, Montesinos P, Altman JK, et al. Pivekimab sunirine (PVEK, IMGN632), a CD123-targeting antibody-drug conjugate, in combination with azacitidine and venetoclax in patients with newly diagnosed acute myeloid leukemia. Blood. 2023;142(Supplement 1):2906–2906. https://doi.org/10.1182/blood-2023-173413.CrossRef

83.

Pelosi E, Castelli G, Testa U. CD123 a therapeutic target for acute myeloid leukemia and blastic plasmocytoid dendritic neoplasm. Int J Mol Sci. 2023;24(3). https://doi.org/10.3390/ijms24032718.

84.

Sallman DA, DeAngelo DJ, Pemmaraju N, et al. Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R/R) CD123+ acute myeloid leukemia (AML). Blood. 2022;140(Supplement 1):2371–2373. https://doi.org/10.1182/blood-2022-169928.

85.

Shahzad M, Nguyen A, Hussain A, et al. Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis. Front Immunol. 2023;14 1152457. https://doi.org/10.3389/fimmu.2023.1152457.

86.

Frankel A, Liu JS, Rizzieri D, et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008;49(3):543–53. https://doi.org/10.1080/10428190701799035.CrossRefPubMed

87.

Lane AA, Garcia JS, Raulston EG, et al. Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2023. https://doi.org/10.1182/bloodadvances.2023011721.CrossRefPubMedPubMedCentral

88.

Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–85. https://doi.org/10.1016/j.cell.2009.05.046.CrossRefPubMedPubMedCentral

89.

Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE. 2015;10(9): e0137345. https://doi.org/10.1371/journal.pone.0137345.CrossRefPubMedPubMedCentral

90.

Daver N, Senapati J, Maiti A, et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML. Blood. 2022;140(Supplement 1):141–4. https://doi.org/10.1182/blood-2022-170188.CrossRef

91.

Safety concerns prompt pause of magrolimab trials. Cancer Discov. 2022;12(4):877–878. https://doi.org/10.1158/2159-8290.cd-nb2022-0012.

Title: Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Authors: Michael Wysota
Marina Konopleva
Shane Mitchell
Publication date: 19-03-2024
Publisher: Springer US
Keywords: Acute Myeloid Leukemia
Molecular Genetics
Gilteritinib
Sorafenib
Hematologic Cancer
Published in: Current Oncology Reports / Issue 4/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01503-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2024

Lymph node dissection in testicular cancer

Update on the management of bone metastases

Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas

Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry

Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma

Metronomic Chemotherapy in Elderly Patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer